|
Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. It was initially approved by the U.S. Food and Drug Administration (FDA) in 2006. It is very expensive as of 2012. ==Medical uses== Lubiprostone is used for the treatment of chronic constipation of unknown cause in adults, as well as irritable bowel syndrome associated with constipation in women.〔(【引用サイトリンク】url=http://www.drugs.com/monograph/amitiza.html )〕 Lubiprostone is approved to treat chronic idiopathic constipation (CIC) in adults. Lubiprostone is also approved to treat opioid-induced constipation, in adults with chronic non-cancer pain. The effectiveness of lubiprostone has not been established in patients who are taking a diphenylheptane opioid (e.g., methadone). Lubiprostone is approved to treat irritable bowel syndrome with constipation (IBS-C) in women 18 years of age and older. As of 12 November 2014, lubiprostone has not been studied in children. There is current research underway to determine the safety and efficacy in postoperative bowel dysfunction. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Lubiprostone」の詳細全文を読む スポンサード リンク
|